Kinase Inhibitors Global Market Report 2024

The kinase inhibitors market size has grown strongly in recent years. It will grow from $58.49 billion in 2023 to $62.75 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to several factors, including the increasing prevalence of cancer, advancements in targeted therapy approaches, rising healthcare expenditures, the approval of new kinase inhibitors, and the growing adoption of personalized medicine strategies.

The kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $83.56 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period can be attributed to ongoing research and development initiatives, the introduction of novel kinase inhibitors, the widening scope of applications beyond oncology, increased investments in biotechnology, and heightened awareness about precision medicine. Major trends expected during this period include the expansion of precision oncology treatments, the development of combination therapies, a greater focus on rare and difficult-to-treat cancers, advancements in biomarker-driven drug development, and the increased adoption of next-generation sequencing technologies.

The rising prevalence of autoimmune diseases is expected to drive growth in the kinase inhibitors market. Autoimmune diseases encompass a range of disorders where the immune system erroneously attacks healthy cells, tissues, and organs, leading to damage. Lifestyle changes, environmental factors, genetic factors, stress, microbial imbalances, and the increasing incidence of chronic diseases such as obesity and diabetes contribute to the growing prevalence of autoimmune diseases. Kinase inhibitors offer therapeutic benefits for autoimmune conditions by modulating the immune system, reducing inflammation, and easing symptoms such as those seen in psoriatic and rheumatoid arthritis. For example, as of December 2022, the National Psoriasis Foundation reported over 8 million cases of psoriasis in the United States and 125 million globally, affecting about 2 to 3% of the population. Additionally, in September 2022, the Centers for Disease Control and Prevention stated that 28.7 million people in the US had diabetes, with 5.7% requiring insulin for type 1 diabetes. This increase in autoimmune disease instances is thus fueling the growth of the kinase inhibitors market.

Leading companies in the kinase inhibitors sector are focusing on developing selective tyrosine kinase 2 (TYK2) inhibitors to meet the demand for treating autoimmune and inflammatory diseases. These inhibitors also play a role in cancer treatment by modulating immune responses, reducing inflammation, and creating an unfavorable environment for tumor growth. For instance, in September 2022, Bristol-Myers Squibb Company gained FDA approval for Sotyktu (deucravacitinib), an oral selective TYK2 inhibitor for treating moderate-to-severe plaque psoriasis in adults needing systemic therapy or phototherapy. This approval signifies a significant step forward in addressing plaque psoriasis, offering a new option for patients with inadequate responses to current treatments.

In August 2022, Bristol Myers Squibb acquired Turning Point Therapeutics Inc. for $4.1 billion, strengthening its position in kinase inhibitors. This acquisition included late-stage kinase inhibitor candidate repotrectinib, expanding BMS's precision oncology portfolio and enhancing its capabilities in treating ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. Turning Point Therapeutics Inc. is known for designing and developing small-molecule tyrosine kinase inhibitors (TKIs).

Major companies operating in the kinase inhibitors market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Astellas Pharma Inc, Cipla Inc, Dr. Reddy's Laboratories Ltd, Endo International Inc., Amneal Pharmaceuticals LLC, Lupin Limited, Exelixis Inc, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals Ltd, Hutchison China MediTech Limited, Akorn Incorporated, Ocular Therapeutix Inc., Sierra Oncology Inc.

Asia-Pacific was the largest region in the kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kinase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kinase inhibitors are medications designed to inhibit the activity of kinases, crucial enzymes involved in cellular processes such as growth and signaling. These inhibitors are primarily utilized in cancer treatment, where they disrupt pathways responsible for cancer cell proliferation and metastasis. Additionally, kinase inhibitors find application in managing inflammatory disorders and other conditions characterized by abnormal kinase function.

The main categories of kinase inhibitors include tyrosine kinase inhibitors, multikinase inhibitors, mTOR kinase inhibitors, and others. Tyrosine kinase inhibitors specifically target enzymes known as tyrosine kinases, which play a role in cancer cell growth. These inhibitors can be administered via oral, parenteral, and other routes, catering to treatment needs in oncology and inflammatory diseases. They are distributed through various channels such as hospital pharmacies, online pharmacies, and retail outlets, serving patients in hospital settings, homecare, specialty clinics, and other healthcare environments.

The kinase inhibitors market research report is one of a series of new reports that provides kinase inhibitors market statistics, including the kinase inhibitors industry global market size, regional shares, competitors with kinase inhibitors market share, detailed kinase inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the kinase inhibitors industry. This kinase inhibitors market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kinase inhibitors market consists of sales of BCR-ABL Inhibitors, ALK Inhibitors, lapatinib, cabozantinib, and sunitinib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.